About Us

Prangenix Section

From Diagnosis to Discovery—A New Era in Precision Healthcare Begins Here

Prangenix integrates multi-omics molecular profiling with AI-driven analysis to detect disease earlier, monitor it more precisely, and target previously inaccessible cell states.

At Prangenix Therapeutics, we’re not just building tests—we’re building trust, transforming outcomes, and pushing the boundaries of what’s possible in personalized medicine.

Rooted in Eastern Uttar Pradesh, we are an Indian biotechnology company revolutionizing cancer diagnostics and therapeutic innovation using molecular precision and stem cell science. Our aim is simple yet bold: make early detection and individualized treatment available to everyone, everywhere.

🎯

Our Mission

To empower clinicians and researchers with rapid, modular diagnostics for cancer and chronic diseases—and to design next-gen therapeutics by unlocking quiescent stem cell biology.

👁️

Our Vision

Prangenix is a platform-first biotech company integrating multi-omics diagnostics and therapeutics targeting quiescent stem cells.

Our Diagnostic process

Molecular Profiling

By applying multi-omics strategies—genomics, transcriptomics, proteomics, and epigenomics—we create holistic molecular profiles that highlight essential biomarkers for precision diagnostics and guide the development of targeted therapeutics.

Detection Signal (Dx) and Single-Cell Map

Our liquid biopsy assays detect cfDNA, cfRNA, and miRNA biomarkers, while single-cell sequencing generates high-resolution maps of quiescent stem cells (qSCs), advancing precision diagnostics and enabling more effective therapeutic intervention.

CRISPR Targeting

By combining advanced CRISPR-based gene-editing technologies with powerful AI-driven analytics, we identify and validate therapeutic targets within quiescent stem cells (qSCs), thereby accelerating the development of innovative next-generation precision cancer treatments.

AI Drug Candidate (Rx)

Our AI-driven drug discovery platform seamlessly integrates diverse multi-omics datasets together with experimental CRISPR results to predict, prioritize, and validate the most effective candidate molecules, enabling truly personalized cancer therapeutics and advancing precision oncology research.

Prangenix Therapeutics

Innovating Cancer Care Through Dx & Rx

Pillar 1 — Diagnostics (Dx) — Detect. Monitor.

Current Focus:

A high-confidence liquid biopsy panel for head and neck squamous cell carcinoma (HNSCC), delivering fast and accurate cancer diagnostics.

Future Scope:

An adaptable multi-cancer platform designed to extend into other cancers and chronic diseases including CVD, CKD, and diabetes.

Technology:

Advanced cfDNA, cfRNA, and miRNA profiling integrated with proprietary bioinformatics pipelines for high-sensitivity and high-specificity detection.

Monitoring Capability:

Quantitative biomarker readouts enable longitudinal patient monitoring for disease progression, therapy response tracking, and personalized treatment planning.

Pillar 2 — Therapeutics (Rx) — Target.

Focus:

Developing precision-targeted therapies against qSCs to overcome therapy resistance and improve long-term patient outcomes.

Approach:

Integrating single-cell sequencing, CRISPR functional genomics, and AI-driven drug design to identify vulnerabilities and create precision oncology solutions.

Initial Target:

HNSCC quiescent cancer stem cells (qCSCs), with planned expansion into other solid tumors and degenerative diseases.

Vision:

To revolutionize personalized cancer care by transforming molecular insights into clinically actionable therapeutic strategies for multi-disease applications.

Our Values

Precision

Every result is backed by scientific rigor and clinically validated methods

Access

We build technology for Tier 2/3 cities, not just metro hospitals

Transparency

Clear reports. Clear communication. No medical jargon wall

Innovation

From liquid biopsy to CRISPR, we invest in what’s next—and make it usable now